Bexsero

**Bexsero** is a multicomponent recombinant protein and outer-membrane-vesicle vaccine developed originally by Novartis Vaccines for prevention of invasive disease caused by *Neisseria meningitidis* serogroup B. The vaccine contains recombinant factor H-binding protein, Neisserial adhesin A, and Neisserial heparin-binding antigen, plus outer membrane vesicles containing PorA from the NZ98/254 strain; these antigens induce bactericidal antibodies against meningococcal B bacteria. It is aluminum hydroxide-adjuvanted and administered by intramuscular injection. Bexsero is now manufactured by GSK and is approved in the United States for individuals aged 10 through 25 years. ([fda.gov](https://www.fda.gov/media/90996/download))

Brand names

Bexsero

Other names

4CMenBMenB-4CMenB4CMenB 4Cmeningococcal group B vaccinemeningococcal group B vaccine recombinant adsorbedmulticomponent meningococcal group B vaccine